罗氟司特联合噻托溴铵用于慢性阻塞性肺疾病稳定期临床研究  

Clinical Study of Roflumilast Combined with Tiotropium Bromide for Stable Chronic Obstructive Pulmonary Disease

作　　者：肖卫兵 张小燕 杨莹莹 沈斌 XIAO Weibing;ZHANG Xiaoyan;YANG Yingying;SHEN Bin(The Third People's Hospital of Jingzhou,Jingzhou,Hubei,China 434000;The Third People's Hospital of Hubei,Wuhan,Hubei,China 430030)

机构地区：[1]湖北省荆州市第三人民医院,湖北荆州434000 [2]湖北省第三人民医院,湖北武汉430030

出　　处：《中国药业》2024年第4期100-103,共4页China Pharmaceuticals

基　　金：湖北省自然科学基金[2017CFB308]。

摘　　要：目的探讨罗氟司特联合噻托溴铵用于慢性阻塞性肺疾病(COPD)稳定期的临床疗效。方法选取荆州市第三人民医院2022年1月至12月收治的COPD稳定期患者90例,按随机数字表法分为对照组和观察组,各45例。两组患者均予噻托溴铵粉雾剂吸入治疗,观察组患者加用罗氟司特片口服。两组均连续治疗2个月。结果观察组总有效率为93.33%,显著高于对照组的75.56%(P<0.05)。治疗后,两组患者的用力肺活量(FVC)、第1秒用力呼气容积(FEV_(1))、FEV_(1)/FVC均显著升高,6 min步行距离均显著延长,慢性阻塞性肺疾病评估测试(CAT)问卷评分及肿瘤坏死因子-α、白细胞介素6、白三烯B4、基质金属蛋白酶-2水平均显著降低,金属蛋白酶组织抑制因子-2水平均显著升高(P<0.05),且观察组患者的改善幅度更显著(P<0.05)。观察组与对照组不良反应发生率无显著差异(13.33%比11.11%,P>0.05)。结论罗氟司特联合噻托溴铵用于COPD稳定期,可有效改善患者的肺功能和临床症状,降低炎性因子和纤维化指标水平。Objective To investigate the clinical efficacy of roflumilas combined with tiotropium bromide for the stable chronic obstructive pulmonary disease(COPD).Methods A total of 90 patients with stable COPD admitted to the Third People's Hospital of Jingzhou from January to December 2022 were selected and divided into the control group and the observation group by the random number table method,with 45 cases in each group.The patients in the two groups were treated with Tiotropium Bromide Powder for Inhalation,on this basis,the patients in the observation group were treated with Roflumilas Tablets orally.Both groups were treated continuously for two months.Results The total effective rate in the observation group was 93.33%,which was significantly higher than 75.56%in the control group(P<0.05).After treatment,the forced vital capacity(FVC),forced expiratory volume in one second(FEV_(1))and FEV_(1)/FVC in the two groups were significantly higher,the 6-minute walk distance(6MWD)was significantly longer,the COPD Assessment Test(CAT)score,tumor necrosis factor-α(TNF-α),interleukin-6(IL-6),leukotriene B4(LTB4)and matrix metalloproteinase-2(MMP-2)levels were significantly lower,tissue inhibitor of metalloproteinase-2(TIMP-2)level was significantly higher(P<0.05),and those in the observation group were significantly better than those in the control group(P<0.05).The incidence of adverse reactions in the observation group was similar to that in the control group(13.33%vs.11.11%,P>0.05).Conclusion Roflumilas combined with tiotropium bromide for stable COPD can effectively improve the lung function and clinical symptoms of patients,decrease the levels of inflammatory factors and fibrosis indexes.

关 键 词：慢性阻塞性肺疾病 稳定期 罗氟司特 噻托溴铵 肺功能 炎性因子 

分 类 号：R969.4[医药卫生—药理学]